医学
内科学
中期分析
肾病科
前瞻性队列研究
肾脏疾病
急诊医学
临床试验
重症监护医学
作者
Susanne B. Nicholas,Ricardo Correa-Rotter,Nihar R. Desai,Lixin Guo,Sankar D. Navaneethan,Kevin M. Pantalone,Christoph Wanner,Stefanie Hamacher,Samuel Fatoba,Andrea Horvat-Broecker,Antonio Garreta-Rufas,Alain Gay,Martin Merz,David C. Wheeler
标识
DOI:10.1007/s40620-024-02070-y
摘要
Abstract Background Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, improves kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The FINE-REAL study (NCT05348733) aims to evaluate the characteristics and treatment patterns of participants treated with finerenone in clinical practice. Methods FINE-REAL is a prospective, single-arm, non-interventional study of patients initiated on finerenone as part of their routine care in accordance with country-approved labels. The study, initiated in June 2022, is expected to be completed by January 2028. The cutoff for this pre-specified interim analysis was June 13, 2023. Results Participants were recruited across nephrology, endocrinology, cardiology, and primary care settings. Of 556 participants enrolled in the study by the cut-off date, 504 were included in this analysis (median follow-up duration of 7 months [finerenone treatment initiation to last recorded observation]). At baseline, 76.1% of participants were in the high or very high (KDIGO) CKD risk categories. Angiotensin converting enzyme inhibitors/angiotensin receptor blockers and sodium–glucose cotransporter 2 inhibitors were prescribed to 71.8% and 46.6% of participants, respectively. Based on prescribing information, 87.9% and 12.1% of participants initiated finerenone at doses of 10 and 20 mg, respectively. Finerenone treatment was uninterrupted in 92.3% of participants after 7 months’ median follow-up. Treatment-emergent adverse events occurred in 110 (21.8%) participants. Hyperkalemia occurred in 25 (5.0%) participants, with no cases leading to death, dialysis, or hospitalization. Conclusion At this interim analysis, finerenone was initiated in patients with CKD and T2D across various clinical practices participating in the study. Treatment discontinuation and hyperkalemia occurred infrequently. Graphical abstract
科研通智能强力驱动
Strongly Powered by AbleSci AI